Loading REGN charts…
May we use analytics cookies to see how vpside is used, including anonymous session recordings? Accepting also loads the price chart, which sets its own cookies. Essential cookies are always on. Privacy
Loading REGN comparable companies…
| REGNRegeneron Pharmaceuticals, Inc.(opens in a new tab) | $97.96B | $16.90B | +18.6% | 96.5% | 28.8% | 5.80× | 20.5× |
|---|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals Inc. / Ma(opens in a new tab) | $142.67B | $12.59B | +10.2% | 86.0% | 38.0% | 11.33× | 32.6× |
| AMGNAmgen Inc.(opens in a new tab) | $253.56B | $38.09B | +9.1% | 69.5% | 30.0% | 6.66× | 29.0× |
| GILDGilead Sciences, Inc.(opens in a new tab) | $213.86B | $30.99B | +6.5% | 79.9% | −7.6% | 6.90× | — |
| ALNYAlnylam Pharmaceuticals, Inc.(opens in a new tab) | $22.76B | $5.01B | +56.2% | 77.4% | 19.5% | 4.54× | 8.6× |
| Medianpeers, excl. REGN | $178.26B | $21.79B | +9.7% | 78.6% | 24.7% | 6.78× | 29.0× |